Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen by unknown
Brief De~m'~ve  Report 
Identification of HLA-DRc~ Chain Residues Critical 
for Binding of the Toxic Shock Syndrome Toxin 
Superantigen 
By Paola  Panina-Bordignon,*~ Xin-ting  Furl  Antonio Lanzavecchia,* 
and Robert  W.  Karts 
From the *Basel Institute for Immunology, CH-4005 Basel, Switzerland; the ~Institut de 
Chimie Biologique, Universitd de Strasbour~ 67000 Strasbourg, France; and the $Department of 
Immunology, Monsanto Company, St. Louis, Missouri 63198 
Summary 
Staphylococcal toxic shock syndrome toxin 1 (TSST-1) binds to major histocompatibility complex 
class II molecules, and the toxin-class  II complexes induce proliferation  of T  ceils expressing 
VB2 sequences. To define the residues involved in TSST-1 binding, a set of transfectants expressing 
21 HLA-DRot chain mutants were analyzed for their abilities to bind and present TSST-1 and 
to present an antigenic peptide. Mutations at DRc~ positions 36 and 39 markedly decreased the 
ability of the DR7 molecule to bind and present TSST-1 but did not affect the ability to present 
an antigenic peptide. These data indicate that DRot residues 36 and 39, predicted to be located 
on an outer loop, are important in the formation of the TSST-1 binding site on DR molecules. 
B 
acterial superantigens  bind to MHC class II molecules 
and are recognized by specific TCRs inducing potent 
activation of T cells (1-3). They include Staphylococcus aureus 
enterotoxins (SE)A, SEB, SEC-1, -2, and -3, SED, and SEE, 
and the exotoxin toxic shock syndrome toxin (TSST-1). TSST-1, 
the focus  of this  report,  is  produced by most  strains  of 
S. aureus that cause toxic shock syndrome and appears to be 
important in the pathophysiology of this disorder (see  refer- 
ence 4 for review and references). In humans, TSST-1 binds 
well to HLA-DR, interacting with a not-yet-defined region 
of the DRod domain (5), but poorly or not at all to DP 
molecules (5-7), and it is specifically recognized by TCRs 
expressing V32 sequences. However, despite the remarkable 
degree of structural, regulatory, and functional conservation 
between DRot and I-Eol chains (8), TSST-1 does not bind 
or binds only at a very low degree to routine I-E molecules 
(7, 9). Based on previous studies, the view has emerged that 
bacterial superantigens interact with class II molecules differ- 
ently than antigenic peptides, perhaps by interactions with 
the outer surface of these molecules (5,  10,  11). 
The purpose of this study was to define specific residues 
in the DRc~ chain that are involved in binding and presenta- 
tion of TSST-1 as compared with presentation of an antigenic 
peptide.  Residues from I-E, DP, or DQot chains were sub- 
stituted into several analogous positions in the DRot chain, 
and mutant DRot chains were expressed in transfectants with 
the wild-type DR(/31"0701) chain. The abilities of these mu- 
tant and wild-type molecules to bind and present TSST-1 to 
T cells and to present an antigenic peptide to antigen-specific 
T cell clones were analyzed. The data indicate that the sub- 
stitutions at DKot residues 36 and 39 caused a significant 
reduction in the ability of the DR7 molecule to bind and 
present TSST-1, whereas substitutions  at positions 24 and 65 
abrogated  recognition by the tetanus  toxin-specific  T  cell 
clones. 
Materials and Methods 
eDNA Clones and Site-directed Mutagenesis.  cDNA clones en- 
coding full-length HLA-DR(cx) and DR(~l"0701) chains (12) in 
the pcD expression  vector  (13) were  used  in this study.  Site-directed 
mutagenesis  of the DRc~  chain  was performed  by the PCR overlap 
extension method (14), using Taq DNA polymerase  and a DNA 
Thermal Cycler (Perkin Elmer Cetus, Norwalk, CT). The four 
17-mer primers  used in the amplifications  were  located  on the pcD 
vector near the 5' end of the cDNA, around the desired  mutation 
positions, and codons corresponding  to amino acids 145-150 of 
the DRc~ chain, respectively.  After the two-step PCK amplifica- 
tions, the PCK-amplified  fragment containing the mutation was 
digested  with the restriction  enzymes  SacI (New England  Biolabs, 
Beverly, MA) and Csp45I (Promega  Biotec, Madison, WI). The 
476-bp SacI-Csp45I fragment from the 5'-untranslated  region to 
the codon corresponding  to amino acid 123 of the DRc~  chain was 
ligated into the SacI-Csp45I-digested  pcD vector containing the 
remainder  of the DRA cDNA. Dideoxy  sequencing  with Sequenase 
T7 DNA polymerase  (United States  Biochemical  Corp., Cleveland, 
OH) of the region between the Sad and Csp45I sites was used 
to confirm the presence of the desired mutation and absence of 
misincorporations. 
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fected with the wild-type DRBI*0701 cDNA into the DAP.3 sub- 
done of class II-negative routine L  fibroblasts as described (12). 
Binding of TSST-1 to DR-transfected Cells.  Purified TSST-1 was 
purchased lyophilized from Toxin Technologies (Madison, WI), 
dissolved in sterile water at a concentration of 1 mg/ml, and diluted 
in PBS just before use. 104 transfected L cells were washed, placed 
into individual microtiter wells, and incubated with various con- 
centrations of TSST-1 for 2 h on ice.  The cells were washed and 
incubated with  a  rabbit anti-TSST-1  serum (Toxin Technology) 
diluted 1:100 in PBS,  1% BSA, 0.01%  NAN3, and incubated on 
ice for 30 rain. The cells were washed and incubated with FITC- 
labeled swine anti-rabbit Ig (Silenus Laboratories, Hawthorn, Aus- 
tralia) on ice for 30 rain. The cells were washed and analyzed by 
flow cytometry on a FACScan  |  (Becton Dickinson & Co., Moun- 
tain View, CA). Controls were incubated with rabbit anti-TSST-1 
and FITC antibody without prior addition of TSST-1. The results 
are presented as the relative fluorescence of the cells stained with 
TSST-1  normalized to the fluorescence of the same cells  stained 
with an anti-DR mAb, as described in the legend to Fig. 1. L243 
was used to assess expression on all mutants except those at posi- 
tions 18 and 39, because these mutations interfere with binding 
of L243 to DR7 molecules (Fu, X., and R. W. Karr, manuscript 
in preparation). SG157 (obtained from Sanna Goyert, North Shore 
University Hospital, Manhasset, NY) (15) and SFR16-DR7 (ob- 
tained from Susan Radka, Oncogen, Seattle, WA) (16) were used 
to assess DR expression on the position 18 and 39 mutants, respec- 
tively. 
T Cell Clones and Proliferation Assay.  T cell clones specific for 
TSST-1 were derived from PBL stimulated in vitro with 50 ng/ml 
of TSST-1. After 7 d the cells were cloned by limiting dilution as 
described (17). T cell clones specific for the tetanus toxin (tt) pep- 
Table  1.  Summary of the Ability of Transfectants Expressing DRce Mutants  to Bind TSST-1  and Present TSST-I  and a  Tetanus 
Toxin Peptide to  T  Cell  Clones 
DRc~  Source of  TSST-1  TSST-1  tt  830-843 
position  Substitution  substitution  binding*  presentation*  prtsentation  s 
7  I-S  DP,  DQc~  +  +  +  +  + 
9  Q-G  DQ,  I-Aot  +  +  +  +  + 
11  E-A  DPo~  +  +  +  + 
15  N-L  I-Ec~  +  +  +  +  + 
18  Q-K  I-Ec~  +  +  +  +  + 
19  S-R  IEc~  +  +  +  + 
22  F-Y  I-E, DQ,  IAcr  +  +  +  - 
24  F-H  DQ,  l-Ac~  +  +  - 
31  I-E  DQc~  +  +  +  + 
36  M-I  I-Ea  -  -  + 
37  A-E  I-Ec~  +  +  +  +  + 
39  K-S  I-Ec~  -  -  + 
42  V-I  I-E, I-Ac~  +  +  +  +  + 
47  E-L  DQc~  +  +  +  +  +  + 
49  G-A  I-E, I-Ac~  +  +  +  +  + 
50  R-K  DQ,  I-Ec~  +  +  +  + 
55  E-D  DQ,  I-Aot  +  +  +  + 
65  V-I  DPc~  +  +  +  - 
6611  D-V  I-Ac~  -  +  +  - 
66  D-L  DQ,  DPc~  +  +  +  ND 
72  I-V  I-Ec~  +  +  +  + 
* The ability of each mutant to bind TSST-1 is categorized  as follows:  -,  TSST-1 concentration required  to induce 50% of wild-type binding 
is >5 #g/ml;  +, TSST-1 concentration required to induce 50% of wild-type binding is between 5 and 1/~g/ml;  + +, TSST-1 concentration re- 
quired to induce 50% of wild-type binding is <1/zg/ml. TSST-1 binding to each mutant was analyzed at least five times. 
* The ability of each mutant to present TSST-1 to at least three different TSST-l-specific T cell clones is categorized as follows:  -, TSST-1 concen- 
tration required to induce 50% of proliferative response to the wild type is >10 ng/ml; +, TSST-1 concentration required to induce 50% of prolifer- 
ative response to the wild-type is between 0.1 and 10 ng/ml;  + +, TSST-1 concentration required to induce 50% of proliferative response to the 
wild-type is <0.1 ng/ml. 
S The ability of each mutant to present tt 830-843  to three different peptide-specific T cell clones is categorized as follows:  -, peptide concentra- 
tion required to induce 50% of proliferative response to the wild type is >10/zg/ml;  +, peptide concentration required to induce 50% of prolifera- 
tive response to the wild type is between 0.1 and 10/~g/ml;  + +, peptide concentration required  to induce 50% of proliferative response to the 
wild type is <0.1/~g/ml. 
II In this case, the expression of DR was always low (for analysis of DR expression see Materials and Methods). 
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of Brown et al. (18) (reprinted by permission from Nature[Land.]. 332:845, 
1988). The DRr~ chain is open and the DIL3 chain is shaded. DR(x residues 
whose side chains are predicted to point into the peptide binding groove 
are shown as shaded circles and those on the outer loops whose side chains 
point away from the binding groove are shown as filled circles. 
tide 830-843 were isolated and characterized as described (17). Three 
independent DR7-restricted, tt830-843-specific  T cell dones (SP6.6, 
SP2.2, and SP3.12)  and four TSST-l-specific  T cell clones (ALp2.12.2, 
AL15.1, BR7.3, and GM2.11) were used. Cultures  were set up in 
200 gl of RPMI 1640 with 10% FCS in flat-bottomed  microtiter 
plates. T cells (4  x  104) were cultured  with 2  x  104 mitomycin 
C-treated L cells that had been pulsed for 2 h at 37°C with various 
concentrations  of either  TSST-1 or tt 830-843  and washed four 
times. After 2 d at 37°C, 5% CO2, the cultures were pulsed with 
1 /~Ci (37 kBq)  [3H]thymidine  (sp  act,  5 Ci/mM;  Amersham 
Corp., Arlington  Heights,  IL), and the incorporated radioactivity 
was measured after an additional  18 h by liquid  scintillation. 
Results and Discussion 
Production of  DRcr Mutants.  To analyze the contribution 
of individual amino acids in the ol chain of HLA-DR mole- 
cules in the interaction with TSST-1, 21 mutated DR7 mole- 
cules containing single amino acid substitutions in the oe chain 
were constructed by site-directed mutagenesis and transfected 
in mouse L ceUs. Since human HLA-DP and murine I-E mol- 
ecules do not bind TSST-1, or bind it poorly, and I-E mole- 
cules do not present TSST-1 (5-7, 9), most of the mutations 
involve replacement  of the  DRol  residue  with  the  corre- 
sponding residue from the c~ chain of HLA-DP or I-E mole- 
cules, as shown in Table 1. The predicted location of the sub- 
stituted positions in the class II molecule, according to the 
model of Brown et al. (18), are shown in Fig. 1. The residues 
at positions 7, 9,  11, 22, 24, and 31 are predicted to be lo- 
cated on the floor of the peptide binding groove, with their 
side chains pointing up toward the peptide binding groove. 
The residues at positions 15,  18, and 19 are predicted to be 
located on the outer loop that connects the first and second 
/~ strands.  The residues at positions 36, 37, 39,  and 42 are 
predicted to be located on an outer loop that connects the 
third and fourth 3  strands.  The residues at positions 47, 49, 
50, 55, 65, 66, and 72 are predicted to be located in the oe 
helix with their side chains pointing in toward the peptide 
binding groove. The level of DR expression by the various 
transfectants was tested before each experiment by indirect 
immunofluorescence utilizing three different anti-DR mAbs 
and flow cytometric analysis.  All the transfectants  utilized 
in this study showed good levels of DR expression with at 
least one of the mAbs utilized,  except the 66 D-V mutant 
that  had  a low level  of expression. 
Binding of TSST1 to HLA-DR7 Molecules and Stimulation 
of V~2 + T  Cell  Clones Are Affected  by Mutations at  Two 
Residues on the Outer Loop of the ol Chain.  Mouse L cells 
expressing wild-type or mutant DR7 molecules were tested 
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Figure 2.  Binding of TSST-1 to 
HLA-DR7 molecules and stimula- 
tion of a VB2 + T  cell clone.  (a) 
Relative  binding  of  TSST-1  to 
wild-type  and  c,  chain-mutated 
DR(B1*0701) molecules. Mouse L 
ceils  were transfected  with wild-type 
or ~ chain-mutated molecules and 
tested  for  their  abilities  to  bind 
different concentrations of TSST-1. 
The Faxis is the rehtive binding  of 
TSST-I  as measured  by  cytofluorom- 
etry. The relative binding was cal- 
culated for each transfectant in the 
following three steps. The net mean 
fluorescence with TSST-1 was cal- 
culated for each sample by subtracting  the linear mean fluorescence obtained with rabbit anti-TSST-1  and FITC-swine anti-rabbit in the absence of 
TSST-1 from that obtained in the presence of TSST-1. The net mean fluorescence with anti-HLA-DR was calculated by subtracting  the linear mean 
fluorescence obtained  with FITC-goat anti-mouse alone from that obtained with the anti-DR antibody  and FITC-goat anti-mouse. The relative fluores- 
cence intensity for TSST-1 was normalized for variations in the level of DR e~pression on various transfectants by dividing the net mean fluorescence 
with TSST-1  by the net mean fluorescence with anti-DR. L cells expressing wild-type DR7 (WT), DR731-DRcOQ-G point mutant (9Q-G), DR731- 
DRoD6M-I point mutant (36 M-I), or DR731-DRo~39K-S point mutant (39 K-S) were used. (b) Proliferation of T cell clone ALp2.12.2 to TSST-1 
presented by wild-type and ~x chain-mutated HLA-DR7B1  molecules. The T cell clone ALp2.12.2, expressing the V32 segment of the TCR, was 
incubated with L cells transfected with wild-type or ot chain-mutated DR731 molecules pulsed with the indicated concentrations  of TSST-1. The 
induced T  cell proliferation was measured by [~H]thymidine incorporation.  Each point represents the mean of triplicate determinations. 
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sentative experiment are shown in Fig.  2 a  and data from 
multiple experiments are summarized in Table 1. We found 
a marked difference in the level of binding of TSST-1 (cor- 
rected for DR expression) between the wild-type and the 
mutants at residues 36, 39, and 66 (D-V). The level of class 
II expression by the transfectant expressing the 66 D-V mu- 
tant was consistently lower than the other transfectants; there- 
fore, the apparent absence of binding to the 66 D-V mutant 
must be interpreted cautiously. There was no significant differ- 
ence in the level of binding of TSST-1 between the wild-type 
and the other mutants. The residues at positions 36 and 39 
were replaced with the residues found at the same positions 
of the murine I-Ec~ chain, which binds TSST-1 poorly or not 
at all (6,  7, 9).  We also calculated the estimated affinity of 
TSST-1 for the wild-type molecule and for the various mu- 
tant molecules using the double reciprocal plot method pre- 
viously described for the calculation of the affinity ofhapten- 
antibody interaction (19). The estimated affinity is expressed 
as K0 and it is equal to the reciprocal of the free TSST-1 con- 
centration at which half the concentration of MHC binding 
sites are bound to TSST-1. We found that the K0 of TSST-1 
binding for the wild-type is 1.8  ￿  10 -7 M,  while the Ko 
for the point mutants at residues 36 and 39 are 10-fold higher, 
being  1.6  and  1.1  x  10 -6 M,  respectively.  This indicates 
that the methionine at position 36 and the lysine at position 
39 are critical for TSST-1 binding. 
In a previous study, it was found that T cell proliferation 
is a more sensitive assay for TSST-l-class II interaction than 
the binding assay. TSST-1 binding to HLA-DP was not de- 
tected, although DP efficiently presented TSST-1 to T cells 
(7, 20). Therefore, the ability of the DRcr mutants to present 
TSST-1 to three specific T cells was tested. The dose-response 
curves of one representative T  cell clone with transfectants 
expressing wild-type or mutant DRcr chains (Fig. 2 b) show 
that, consistent with the results obtained in the direct binding 
assay, mutations at positions 36 and 39 significantly reduce 
the recognition of TSST-1 by the T cell. In contrast, the 66 
D-V mutant presented TSST-1 to the T cell clones, suggesting 
that the failure to detect TSST-1 binding to this mutant was 
due to low class II expression. All the other mutants presented 
TSST-1 to the T cell clones, indicating that the MHC-TSST-1 
complex is not altered by the introduction of the mutation. 
Interestingly, the nonconservative 37 K-S substitution had 
no effect on TSST-1 binding or presentation, in contrast with 
the results with the position 36 and 39 mutations. These results 
are consistent with the predictions of the class II model and 
the view that superantigens interact with the outer surfaces 
of class II molecules: although residues 36,  37,  and 39 are 
predicted to be located on an outer loop, only the side chain 
of residue 37 is predicted to point in toward the peptide binding 
groove. 
Presentation of tt 830-843  by Transfectants Expressing DRol 
Mutants.  To assess whether any of the single substitutions 
in the DRo~ chain causes gross alterations of the conformation 
of the DR molecules, we tested the ability of these mutants 
to present peptide antigen. Three independent DR7-restricted 
T cell clones were tested for their abilities  to recognize pep- 
tide tt 830-843 presented by transfected cells. The prolifera- 
tive response of one representative clone is shown in Fig. 3. 
We found that the substitutions of a methionine to an isoleu- 
cine at residue 36 and of a lysine to a serine at residue 39 
do not affect the ability of these mutants to present peptide 
antigen. This indicates that the mutants bind the peptide and 
that the peptide-MHC complex is recognized by the specific 
TCR. Our results are consistent with the view that the binding 
site for toxin superantigens is different from the conventional 
antigen binding site (5, 10, 11). We also found that substitu- 
tions at positions 24 and 65  abrogated recognition by the 
tt-specific T  cells, although they have no effect on TSST-1 
binding and presentation. The substitutions at positions 22 
and 66 D-V reduced the ability of the DR7 molecule to present 
peptide. The findings that only 2 of the 21 DRcr mutations 
abrogated the ability of the DR7 molecule to present the 
tt peptide to the three T cell clones are in marked contrast 
to the results of our previous analysis of DRB mutations on 
tt presentation in which multiple mutations abrogated T cell 
proliferation (21). For example, proliferation by clone SP6.6 
was abrogated by mutations at DRfl positions  11,  57,  60, 
67, and 70, and clone SP3.12 at positions 11, 13, 57, 67, 70, 
74,  and 78. 
Concluding Remarks.  The present study demonstrates that 
residues 36 and 39 on the DRo~ chain are critical for TSST-1 
binding and presentation to specific T cells. Recently it has 
been demonstrated that the second hypervariable region of 
the mouse Ac~ chain (olHV2) is the single most important 
c~ chain polymorphic region that contributes to the TSST-1 
binding site (22).  Indeed, residues 36 and 39 are predicted 
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Figure 3.  Proliferation of T cell clone SP6.6 to tt 830-843  presented 
by wild-type and  a  chain-mutated  HLA-DRT~81 molecules.  The  tt 
830-843-specific T cell clone SP6.6 was incubated with L cells transfected 
with wild-type or cr chain-mutated DR7~81 molecules pulsed with the 
indicated concentrations of tt 830-843.  The induced T cell proliferation 
was measured by [3H]thymidine incorporation. Each point represents the 
mean of triplicate determinations. L celts expressing wild-type  DR7 (WT), 
DP,7B1-DRo~2,4F-H point mutant (24 F-H), DR7t51-DR~36M-I point 
mutant (36 M-I), DR7~I-DRo~39K-S point mutant (39 K-S), or DR7B1- 
DlZc~65V-I point mutant (65 V-I) were used. 
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loop of the c~ chain that connects the third and the fourth 
strands.  Our data suggest the existence of a high a~nity 
binding site on DILc~ chain for TSST-1,  since alteration of 
two closely located residues, 36 and 39, can significantly re- 
duce TSST-1  binding  and  presentation.  However, at  high 
TSST-1 concentrations a certain level of binding and presen- 
tation by these mutants is observed (Fig. 2), indicating that 
a low ai~nity binding site might still be available. Therefore, 
the substitution at one residue may decrease the af~nity of 
TSST-1 binding to MHC, rather than abolishing the binding. 
Previous studies indicate the existence of different binding 
sites,  some of which may be overlapping, for staphylococcal 
toxins on class II molecules (23, 24). Two SEA binding sites 
have been postulated, but previous studies indicate a single 
TSST-1 binding site. DRB residue 81, which is predicted to 
be located in a region of interchain  interaction with the oe 
chain,  has been shown to be involved in the SEA and SEE 
binding  site (11, 25).  We found that  a histidine  to alanine 
substitution at position 81 in the DIL(~l*0701) chain does 
not  prevent binding  and presentation  of TSST-1  (data not 
shown). However, analysis  of TSST-1 binding to additional 
mutants will be required to further investigate the possible 
contributions of DRB chain residues to TSST-1 binding (22). 
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